Top Spanish drugmaker fears disruption if EMA moves from Britain

By Emma Pinedo MADRID (Reuters) - The likely relocation of the European Medicines Agency (EMA) from London threatens to disrupt the approval of new drugs and is a medium and long-term worry for top Spanish drugmaker Almirall, its chief executive said on Monday. The EMA, Europe's equivalent the U.S. Food and Drug Administration, approves medicines for all European Union countries from its headquarters in London's Canary Wharf financial district. After Britain's vote on June 23 to leave the European Union, it is widely expected to transfer to another city within the EU.